It is therefore still unclear, despite the pharmacologically driven properties of these agents supporting their effect on the G1/S phase cell-cycle pathway, how to best ascertain in advance if there is a subset of non–breast cancer patients who may respond to CDK4/6 inhibitors,. Here, CDK4 is linked to breast cancer.